Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jealena Reesor

Nurse Practitioner Winchester, KY Nurse Practitioner

NPI 1124308341 CMS profile 10716873

1520 Boonesboro Rd, Winchester, KY 40391

Open in the dashboard

General payments

$10,096

641 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jealena Reesor of Winchester, KY is reported in the CMS Open Payments database as having received $10,096 across 641 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,335 149
2024 General $2,498 164
2023 General $2,064 134
2022 General $2,015 117
2021 General $1,185 77

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jealena Reesor
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Jealena Reesor were reported at $2,335. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Jealena Reesor Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $1,185 $135 $40–$426 $132
2022 $2,015 $152 $48–$470 $149
2023 $2,064 $166 $54–$529 $160
2024 $2,498 $173 $55–$556 $164
2025 $2,335 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $2,540 144 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $2,149 196 payments
  3. Janssen Biotech, Inc. $873 63 payments
  4. Genzyme Corporation $671 43 payments
  5. Regeneron Healthcare Solutions, Inc. $545 29 payments
  6. Phathom Pharmaceuticals, Inc. $481 33 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $366 22 payments
  8. Janssen Scientific Affairs, LLC $354 4 payments
  9. Ardelyx, Inc. $310 20 payments
  10. Lilly USA, LLC $284 12 payments
  11. Other $1,524 75 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $10,009 639 payments
  2. Education $88 2 payments
Products named General payments · program years 2021–2025
  1. LINZESS $1,458 71 payments
  2. XIFAXAN $1,310 140 payments
  3. CREON $979 49 payments
  4. STELARA $948 49 payments
  5. TRULANCE $727 49 payments
  6. DUPIXENT $671 43 payments
  7. RINVOQ $555 37 payments
  8. MAVYRET $342 21 payments
  9. ZEPOSIA $313 9 payments
  10. IBSRELA $310 20 payments
  11. Other $4,461 276 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 20 drugs

Part D claims

1,081

Median for Nurse Practitioner: 389

Drug cost

$175,071

Median for Nurse Practitioner: $21,885

Branded share of claims

29.6%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Creon Lipase/Protease/Amylase Brand 30 $75,889
Linzess Linaclotide Brand 73 $59,006
Trulance Plecanatide Brand 18 $17,266
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 67 $4,461
Colestipol Hcl Generic 77 $3,366
Pantoprazole Sodium Generic 312 $3,061
Dexlansoprazole Dr Dexlansoprazole Brand 20 $3,025
Peg3350-Sod Sul-Nacl-Kcl-Asb-C Peg3350/Sod Sul/Nacl/Kcl/Asb/C Brand 32 $2,245
Plenvu Peg3350/Sod Sul/Nacl/Kcl/Asb/C Brand 11 $1,535
Ondansetron Hcl Generic 69 $1,448

The 10 drugs with the highest cost, of 20 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 4 billing codes

Paid by Medicare

$16,928

Medicare's payments for the services billed

Medicare patients

178

Average age 71

Services billed

228

110 women, 68 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 49%
Diabetes 35%
Ischemic heart disease 30%
Chronic kidney disease 28%
COPD 27%
Depression 25%
Atrial fibrillation 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $240
  • Regeneron Healthcare Solutions, Inc. $117
$357 — —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $326
$326 — —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $234
$234 — —
STELARA
  • Janssen Biotech, Inc. $178
$178 — —
ENTYVIO
  • Takeda Pharmaceuticals U.S.A., Inc. $166
$166 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

641 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record